DiaMedica Therapeutics (DMAC) Free Cash Flow (2018 - 2026)

DiaMedica Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$9.1 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 26.94% year-over-year to -$9.1 million in Q1 2026; TTM through Mar 2026 was -$31.0 million, a 37.31% decrease from a year earlier, with the FY2025 full-year figure at -$29.1 million, down 31.68% from the prior year.
• Free Cash Flow fell to -$9.1 million in Q1 2026 per DMAC's latest filing, from -$7.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$2.4 million in Q3 2022 and bottomed at -$9.1 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$5.0 million (2023), against an average of -$5.3 million.
• Across the five-year window, Free Cash Flow increased 21.13% in 2022 and tumbled 101.2% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$2.8 million in 2022, then slumped by 36.35% to -$3.8 million in 2023, then sank by 68.83% to -$6.4 million in 2024, then decreased by 20.6% to -$7.8 million in 2025, then retreated by 17.02% to -$9.1 million in 2026.
• Per Business Quant, the three latest DMAC Free Cash Flow figures stand at -$9.1 million (Q1 2026), -$7.8 million (Q4 2025), and -$6.6 million (Q3 2025).